Press "Enter" to skip to content

Maximizing Intellectual Property Value in the Biomedical Sector: A Case Study on Rucaparib Patents

Listen to this article
Copyright © DrugPatentWatch. Originally published at

A paper titled “Analysis of Strategy for Extending Patent Protection of Rucaparib” by Zhifeng Wang. discusses the strategies employed by pharmaceutical companies to extend the patent protection period of the drug Rucaparib. Rucaparib is a medication used in the treatment of ovarian cancer and is subject to various patent strategies.

The article highlights several key points:

  • Importance of Compound Patents: Compound patents, especially for the primary active ingredient, are crucial in the pharmaceutical industry. They provide robust protection for the chemical substances or active molecules used in drugs, making it difficult for competitors to circumvent.
  • Crystal Form Protection: Different crystal forms of drugs can offer various advantages, such as improved stability, solubility, and bioavailability. Protecting new crystal forms through patents can effectively extend the patent protection period.
  • Expanding Indications: Pharmaceutical companies often seek to broaden the range of indications for their drugs. This expansion can include targeting different diseases or conditions, thus expanding the consumer base and market reach.
  • Preparation Methods: Optimizing the preparation methods and dosage forms of drugs can be a valuable strategy. This includes developing sustained-release formulations, subcutaneous implants, and other advanced dosage forms.
  • Maximizing Market Monopoly: Extending patent protection allows pharmaceutical companies to maintain a market monopoly for their drugs, preventing or delaying competitors from entering

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at
DrugPatentWatch - Make Better Decisions